We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current NCYT market cap is 30.72M. The company's latest EPS is GBP and P/E is N/A.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 277.2M | 95.78M | 22.49M | 11.58M | 20.18M |
| Operating Income | 167.52M | -7.79M | -33.21M | -30.34M | -46.07M |
| Net Income | 132.42M | -9.73M | -25.73M | -28.29M | -41.76M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 234.28M | 183.7M | 140.9M | 133.82M | 70.63M |
| Total Liabilities | 83.57M | 41.88M | 25.69M | 46.57M | 22.75M |
| Total Equity | 150.71M | 141.82M | 115.22M | 87.24M | 47.88M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | 102.98M | 15.69M | -13.73M | -24.99M | -9.82M |
| Investing | -7.97M | -5.03M | -577k | -13.94M | -1.86M |
| Financing | -5.04M | -599k | -516k | -3.97M | -1.84M |
| Market Cap | 30.72M |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 70.63M |
| Average Volume (1 week) | 80.06k |
| Average Volume (1 Month) | 131.04k |
| 52 Week Change | -5.43% |
| 52 Week High | 137.00 |
| 52 Week Low | 36.10 |
| Spread (Intraday) | 1.1 (2.47%) |
| Company Name | Novacyt S.a. |
| Address |
131 boulevard carnot saint-germain-en-laye, yvelines 78110 |
| Website | https://www.novacyt.com |
| Industry | in vitro,in vivo diagnostics (2835) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
